1416803-88-7

Basic information

• Product Name: 4-(5-(benzo[d]thiazol-2-yloxy)pentyloxy)-N,N-diethyl-3-methoxybenzamide
• Synonyms: 4-(5-(benzo[d]thiazol-2-yloxy)pentyloxy)-N,N-diethyl-3-methoxybenzamide
• CAS NO: 1416803-88-7
• Molecular Weight: 442.579
• Mol File: 1416803-88-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 4-(5-(benzo[d]thiazol-2-yloxy)pentyloxy)-N,N-diethyl-3-methoxybenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(5-(benzo[d]thiazol-2-yloxy)pentyloxy)-N,N-diethyl-3-methoxybenzamide(1416803-88-7)
• EPA Substance Registry System: 4-(5-(benzo[d]thiazol-2-yloxy)pentyloxy)-N,N-diethyl-3-methoxybenzamide(1416803-88-7)

Safety Data

• Hazardous Substances Data: 1416803-88-7(Hazardous Substances Data)

Upstream product

• 934-34-9 2-hydroxybenzothiazole 
• 1416803-79-6 2-(5-chloropentyloxy)benzo[d]thiazole 
• 304-84-7 etamivan 
• 54512-75-3 1-bromo-5-chloropentane 

Relevant articles and documents

Novel diether compounds inhibiting differentiation of osteoclasts

Osteoporosis is a disorder in which bone mass decreases and is responsible for many degenerative bone diseases. The excessive formation and activity of osteoclasts results in pathological disorders of the bone. Receptor Activator of Nuclear Factor κB Ligand (RANKL) is regarded as a key regulator of osteoclast activity and as a new therapeutic target for treating osteoporosis. Herein, we have synthesized several new small molecules and tested their inhibition activity on RANKL-induced osteoclast formation. The active compounds 2c and 4d showed inhibitory activity against RANKL-induced osteoclast differentiation (IC50 = 1.56 and 2.20 μM, respectively). The most active compound 2c prevented LPS-induced osteoclastogenesis in vivo. These data imply that the compound may be the potential candidate for a new therapeutic drug for treatment of bone resorption-associated diseases.